Guidance across all 18 sectors, editable business-model multiples and optional two-stream calculations. Explore your range, review assumptions and save or export your scenarios.
| Method | Valuation | Context |
|---|---|---|
| Equipment · $100K × 1–3 | $100–300K | Illustrative |
| Software · $50K × 4–8 | $200–400K | Illustrative |
| Range midpoint | $500K | Arithmetic, not an asking price |
Most founders pick a valuation from a blog post or a friend's round, and an investor sees through it in seconds.
A valuation is not a guess. It is a claim with evidence behind it. When an investor asks how you got to your number, "comparable rounds" is not an answer. ValuLab shows how expected revenue and chosen multiples change a planning valuation range, so you can explain the assumptions.
Your startup name and sectors come from your profile. Confirm your stage, geography and currency, then choose how your business earns revenue. Sector guidance helps you find the closest model.
Choose software, products, platform fees, business services, education, care, transport, agriculture or specialist commercial models. Enter expected next-12-month revenue and edit the suggested multiples. Add a second stream to sum both ranges. Sources are optional; models without a suitable shared range use your own comparables. Development-stage biotech has a separate programme cash-flow worksheet.
| Metric | Value |
|---|---|
| Expected next-12-month revenue | US$2M |
| Illustrative multiple | 3–5× |
| Editable multiple | 3–5× |
| Valuation | $6–10M |
Save up to three named scenarios with their assumptions and sources. Review the revenue scenarios and the assumptions behind your ask, then download the report. Enter agreed round terms in CapLab.
| Scenario | Valuation |
|---|---|
| Base Case | Needs review |
| Optimistic | $10.2M |
| Conservative | $6.5M |
Choose the way you earn revenue within your sector. Suggested ranges are editable planning judgements informed by dated references, not measured startup deal bands. No extra evidence questionnaire is required.
Where a common revenue multiple does not fit, ValuLab leaves it blank and explains the limitation. Lenders, owned property and energy projects may need a separate equity or asset valuation. The development-stage biotech worksheet estimates one programme, not company pre-money equity.
Use your planning range to prepare for investor discussions, then enter agreed terms in the tools that follow.
Expected revenue and editable multiples, with your assumptions ready to review.
Explore ValuLab →